B
Bertram Pitt
Researcher at University of Michigan
Publications - 834
Citations - 88351
Bertram Pitt is an academic researcher from University of Michigan. The author has contributed to research in topics: Heart failure & Myocardial infarction. The author has an hindex of 107, co-authored 754 publications receiving 78458 citations. Previous affiliations of Bertram Pitt include Rutgers University & Tufts Medical Center.
Papers
More filters
Journal ArticleDOI
Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction.
Gianluigi Savarese,Hong Xu,Marco Trevisan,Ulf Dahlström,Patrick Rossignol,Bertram Pitt,Lars H. Lund,Juan Jesus Carrero +7 more
TL;DR: DysK is common in HF and is associated with increased mortality, and hypoK was associated with increase CVD hospitalizations (HF-related excluded), and there was no association between dysK and HF hospitalization risk, regardless of EF.
Journal ArticleDOI
Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
TL;DR: The Epleronone Post‐Acute Myocardial Infarction Heart Failure Efficacy and Survival Study trial demonstrated that selective aldosterone blockade with eplerenone significantly reduced total mortality, combined cardiovascular mortality and sudden cardiac death.
Journal ArticleDOI
Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction.
Masatoshi Minamisawa,Sara B. Seidelmann,Brian Claggett,Sheila M. Hegde,Amil M. Shah,Akshay S. Desai,Eldrin F. Lewis,Sanjiv J. Shah,Nancy K. Sweitzer,James C. Fang,Inder S. Anand,Eileen O'Meara,Jean L. Rouleau,Bertram Pitt,Scott D. Solomon +14 more
TL;DR: Patients with HFpEF are at an elevated risk for malnutrition, which was associated with an increased risk for CV events in this population, according to the geriatric nutritional risk index.
Journal ArticleDOI
Eplerenone and new‐onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS‐HF)
David Preiss,Dirk J. van Veldhuisen,Naveed Sattar,Henry Krum,Karl Swedberg,Harry Shi,John Vincent,Stuart J. Pocock,Bertram Pitt,Faiez Zannad,Faiez Zannad,John J.V. McMurray +11 more
TL;DR: Though the combination of diabetes and chronic heart failure (CHF) carries a poor prognosis, few studies have examined predictors of new‐onset diabetes in those with CHF and the effect of mineralocorticoid receptor antagonist therapy on new‐ONSet diabetes.
Journal ArticleDOI
Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH study)
Alan S. Maisel,Yang Xue,Dirk J. van Veldhuisen,Adriaan A. Voors,Tiny Jaarsma,Peter S. Pang,Javed Butler,Bertram Pitt,Paul Clopton,Rudolf A. de Boer +9 more
TL;DR: Patients with acute heart failure who received spironolactone during hospitalization had significantly fewer 30-day mortality and HF rehospitalizations, especially in high-risk patients.